JP2022506111A5 - - Google Patents
Info
- Publication number
- JP2022506111A5 JP2022506111A5 JP2021523279A JP2021523279A JP2022506111A5 JP 2022506111 A5 JP2022506111 A5 JP 2022506111A5 JP 2021523279 A JP2021523279 A JP 2021523279A JP 2021523279 A JP2021523279 A JP 2021523279A JP 2022506111 A5 JP2022506111 A5 JP 2022506111A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- eye disease
- pharmaceutical composition
- uveitis
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862751967P | 2018-10-29 | 2018-10-29 | |
| US62/751,967 | 2018-10-29 | ||
| PCT/US2019/056947 WO2020092019A1 (en) | 2018-10-29 | 2019-10-18 | 2-azabicyclo hexane compound as jak inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022506111A JP2022506111A (ja) | 2022-01-17 |
| JP2022506111A5 true JP2022506111A5 (enExample) | 2022-09-01 |
Family
ID=68542755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523279A Withdrawn JP2022506111A (ja) | 2018-10-29 | 2019-10-18 | Ｊａｋ阻害剤としての２－アザビシクロヘキサン化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10968222B2 (enExample) |
| EP (1) | EP3853229A1 (enExample) |
| JP (1) | JP2022506111A (enExample) |
| KR (1) | KR20210084512A (enExample) |
| CN (1) | CN112955451A (enExample) |
| AU (1) | AU2019373059A1 (enExample) |
| BR (1) | BR112021007788A8 (enExample) |
| CA (1) | CA3113667A1 (enExample) |
| IL (1) | IL282460A (enExample) |
| MX (1) | MX2021004582A (enExample) |
| SG (1) | SG11202103042XA (enExample) |
| WO (1) | WO2020092019A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011064631A1 (en) | 2009-10-02 | 2011-06-03 | Foamix Ltd. | Surfactant-free, water-free, foamable compositions and breakable foams and their uses |
| UA123633C2 (uk) | 2015-11-03 | 2021-05-05 | Тереванс Байофарма Ар Енд Ді Айпі, Елелсі | Сполуки інгібітору jak-кінази для лікування респіраторного захворювання |
| US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| FI3837258T3 (fi) | 2018-09-04 | 2024-05-27 | Theravance Biopharma R&D Ip Llc | Dimetyyliaminoatsetidiiniamideja jak-estäjinä |
| JP2021535176A (ja) | 2018-09-04 | 2021-12-16 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | Ｊａｋ阻害剤およびその中間体を調製するためのプロセス |
| UA127328C2 (uk) | 2018-09-04 | 2023-07-19 | Тереванс Байофарма Ар Енд Ді Айпі, Елелсі | 5-7-членні гетероциклічні аміди як інгібітори jak |
| TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
| CN111620868B (zh) * | 2020-05-28 | 2021-08-31 | 爱斯特（成都）生物制药股份有限公司 | 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法 |
| CN111973599A (zh) * | 2020-08-07 | 2020-11-24 | 杭州邦顺制药有限公司 | 用于眼部疾病治疗的化合物 |
| EP4196477A4 (en) * | 2020-08-17 | 2024-10-09 | Vyne Therapeutics Inc. | TOFACITINIB-CONTAINING ANHYDROUS ELASTOMER-BASED GEL FORMULATIONS |
| EP4359402B1 (en) * | 2021-06-25 | 2026-03-11 | Theravance Biopharma R&D IP, LLC | Imidazolo indazole compounds as jak inhibitors |
| CN114181055A (zh) * | 2021-12-21 | 2022-03-15 | 苏州楚凯药业有限公司 | 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法 |
| CN115969796B (zh) * | 2022-12-06 | 2024-07-09 | 苏州大学 | 一种jak抑制剂长效微球及其制备方法与应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| EP1648455A4 (en) | 2003-07-23 | 2009-03-04 | Exelixis Inc | MODULATORS OF ALK PROTEIN (ANAPLASTIC LYMPHOMA KINASE) AND METHODS OF USE |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| WO2010114971A1 (en) | 2009-04-03 | 2010-10-07 | Sepracor Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| LT3001903T (lt) | 2009-12-21 | 2018-01-10 | Samumed, Llc | 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| SI3077395T1 (en) | 2013-12-05 | 2018-03-30 | Pfizer Inc. | Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides |
| KR20170002623A (ko) | 2014-05-14 | 2017-01-06 | 화이자 인코포레이티드 | 피라졸로피리딘 및 피라졸로피리미딘 |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| DK3371185T3 (da) * | 2015-11-03 | 2020-11-30 | Topivert Pharma Ltd | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus-kinase-inhibitorer |
| UA123633C2 (uk) * | 2015-11-03 | 2021-05-05 | Тереванс Байофарма Ар Енд Ді Айпі, Елелсі | Сполуки інгібітору jak-кінази для лікування респіраторного захворювання |
| WO2017077283A1 (en) * | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| WO2018165392A1 (en) | 2017-03-09 | 2018-09-13 | Theravance Biopharma R&D Ip, Llc | Jak inhibitors containing a 4-membered heterocyclic amide |
| KR20200003121A (ko) | 2017-05-01 | 2020-01-08 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 저해제 화합물의 결정형 |
| WO2018204233A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a jak inhibitor compound |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| HUE067145T2 (hu) | 2019-02-25 | 2024-10-28 | Henan Medinno Pharmaceutical Tech Co Ltd | JAK inhibitor vegyület és alkalmazása |
| WO2020181034A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| CN112279848A (zh) | 2019-07-25 | 2021-01-29 | 四川海思科制药有限公司 | 一种泛JAKs抑制剂及其用途 |
-
2019
- 2019-10-18 KR KR1020217015109A patent/KR20210084512A/ko not_active Withdrawn
- 2019-10-18 US US16/656,946 patent/US10968222B2/en not_active Expired - Fee Related
- 2019-10-18 SG SG11202103042XA patent/SG11202103042XA/en unknown
- 2019-10-18 CN CN201980070126.7A patent/CN112955451A/zh active Pending
- 2019-10-18 CA CA3113667A patent/CA3113667A1/en active Pending
- 2019-10-18 EP EP19802351.7A patent/EP3853229A1/en not_active Withdrawn
- 2019-10-18 AU AU2019373059A patent/AU2019373059A1/en not_active Abandoned
- 2019-10-18 JP JP2021523279A patent/JP2022506111A/ja not_active Withdrawn
- 2019-10-18 MX MX2021004582A patent/MX2021004582A/es unknown
- 2019-10-18 WO PCT/US2019/056947 patent/WO2020092019A1/en not_active Ceased
- 2019-10-18 BR BR112021007788A patent/BR112021007788A8/pt not_active Application Discontinuation
-
2021
- 2021-03-01 US US17/249,373 patent/US20210206764A1/en not_active Abandoned
- 2021-04-20 IL IL282460A patent/IL282460A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022506111A5 (enExample) | ||
| US11248000B2 (en) | Quinazoline and indole compounds to treat medical disorders | |
| EP3985002B1 (en) | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders | |
| JP2025084977A5 (enExample) | ||
| JP2023099094A5 (enExample) | ||
| JP2025084976A5 (enExample) | ||
| US11414394B2 (en) | Process for producing a hydrate of a hydrochloride salt of 2,2′-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid | |
| TW201718551A (zh) | 用於治療醫學病症之醯胺化合物 | |
| CN110343135A (zh) | 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐 | |
| TW201720438A (zh) | 用於治療醫學病症之化合物 | |
| JP7061236B2 (ja) | Ｍｔｏｒｃモジュレーターおよびその使用 | |
| CN109069508A (zh) | Ezh2抑制剂及其用途 | |
| WO2017035351A1 (en) | Amino compounds for treatment of medical disorders | |
| CN112839945A (zh) | 补体因子d抑制剂的形态形式 | |
| JP2017524025A5 (enExample) | ||
| JP7330510B2 (ja) | 非滲出型または萎縮型の黄斑変性にて以前に失われた視力を回復させるための医薬組成物 | |
| JP2022519744A5 (enExample) | ||
| US20230022157A1 (en) | Pharmaceutical compounds for the treatment of complement factor d medical disorders | |
| JP2022519924A (ja) | 補体媒介性障害の治療のための医薬化合物 | |
| JP2021516271A5 (enExample) | ||
| JP2024515826A5 (enExample) | ||
| JP2020535161A5 (enExample) | ||
| JP2021530543A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| JP2022524325A5 (enExample) |